Member Info for Soupdragon78

By coincidence the Oxilio acquisition of Dans LSHS was closed out yesterday.
Still can’t figure out what IP they get from it unless Dan transferred his invention rights for nxp001 to the company.

You ok Terry? Only the other day you were calling NFX a poisoned chalice and a ‘pie in the sky business’

Ps. Lanstead haven’t paid for their shares yet, they pay based on the sp average so will probably be happy it’s this low as they get their share on the cheap.

Trying to dissect the update a bit to figure out where we are at (more in a self help group kind of way).

NXP001
Sits with Oxilio to develop. Oxilio appointed Quotient to undertake development and Phase 1 clinical later this year.

Milestone payments will be made to NFX after clinical trials, possibly this calendar year. (don't care how little at the minute, as said before anything is better than a kick in the love spuds)

NXP002
Further studies will be undertaken 'including evaluation of a new formulation' ... so are they re-running with the original and also doing the new alongside? Or is it just all new formulation?

"New studies will examine both the pharmacokinetics of NXP002 as an inhaled product..." So how the drug is absorbed etc into the body through the lung. Retesting probably with a new formulation to alleviate the inconsistencies encountered.

"and further test its efficacy in repeat LPS challenge studies." To again test durability over time.

Obviously we are at the mercy of available slots at the CRO so we have to wait. But the fact they have a new formula already and its not just a case of walking away from it must be positive.

NXP004
"The Company has previously demonstrated the enhanced performance of NXP004 compared to olaparib's free form. "

I assume that these are the studies undertaken prior to the November 21 announcement.

"Subsequently, additional pre-formulation studies have been completed confirming the superiority of the Company's recently patented cocrystal forms"

So they have done further work since November, so why was this not announced?

"...and a lead cocrystal has been selected to enter drug product development. "

Selected by who? and to be developed by who?

Management.
Haven't got a clue how this will pan out really. I'd like to think DG would take it up but in reality I can't see that happening.
I still think something will come from an Oxilio direction.

The odd thing is that he was appointed to his new job on the 25th, then released a rubbish RNS on the 30th, before walking on the 31st.

The fact that his resignation was the last to be announced is odd, given he got the job before the update.

Given that the company has been looking for a CEO for months and he hasn't come forward, plus Jivings mention that those in contact with him have said he isn't interested in taking a board role and also that only a few weeks ago he was formalised as director of TRX.

All the above lead to thinking he's not going to be CEO (whilst personally hoping I'm proven wrong)

FX means for him to be back in a more significant way. Whilst he was announced as a consultant, we don't actually know the term he was to cover.... is he still an active consultant?

Part of the problem, putting individual characters to one side, is also that we often forget NFX is a tiny company with no income stream, swimming in an ocean with a vast number of companies with large amounts of cash.
It’s very easy for other companies to tempt people away with not particularly large offers. So we shouldn’t be too surprised that people are lured elsewhere.

Ganners, it appears he couldn’t do either.

Hope Small Pharma have their eyes open, as they’ve appointed him COO, so he’s going to be running the day to day of their business.

Where are you hearing that Kane?
We’ve got an NFX rns saying he left to go to another company, and an announcement from Small Pharma on TSX saying he’s joined as COO, so it seems quite clear cut no?

It appears Riddell moved to be COO of TSX listed Small Pharma, and was announced with their results a few days before our corporate update. Typically the press release makes no mention of his time at NFX so wouldn't have been picked up on my usual searches.

https://smallpharma.com/small-pharma-business-update

Terry, hardly a gravy train. The CEO got 90k and NED's like Gilbert and Kennedy got circa 20k per year.

Agree with that, Stanfords and IFC were brought in for whatever reason by AR once Anne had left. He'd worked with Stanfords before when he set up a subscription placing as Chairman at Feedback.

Before that Wallbrooke actively updated the website and twitter feed and didn't post nonsense linking to irrelevant articles.

Its like AR was doing them a favour by employing them.

You can't make this stuff up, IFC Advisory (who primarily see Directors Talk as the way to message) the inept company PR not only tried to connect NFX to an episode of Neighbours the other week, they've now linked an article with the oh so apt title 'The Definition of Cancer'.

After the past couple of days do they really think that such a phrase and NFX sit well together?!!!

https://*************.net/the-definition-of-cancer

Deejayhaitch, when DG left, the only people celebrating were Offshoresailor and Aberdeenman.

Push. With respect I wouldn’t worry too much about websites. The majority of the internet is filled with out of date info.

Plus even Dan hasn’t even updated own linked in page in over a year with no mention of him being at TRx.

Doesn’t mean he’s not been doing anything no?

Filter. I know what you mean about the level of enthusiasm, still can’t get over the single paragraph in the update on 004, “oh yeah, by the way we’ve done more work on it and it’s superior to a blockbuster but, you know, that’s not important.”

Been looking at the Oxilio announcement on buying Dans consultancy and more and more feel they could take advantage of this clusterfudge.

“ As a result of the transaction, Oxilio secures continuing access to Dr Gooding’s expertise and know-how in both our lipid and co-crystal product development routes.”

“ We are looking forward to continuing close co-operation with Dr Gooding across a range of scientific developments at Oxilio.”

They mention ‘both our lipid and cocrystal product development routes’ and we know they are moving forward with NXP001 as a lipid product, so what cocrystal would they be interested in developing?

Yes is just another straw to clutch at but that’s all I’ve got to keep me sane at the minute.

Fag packet figures but by my calcs, Lanstead are currently down about £80k on their investment so far.

Based on, they should have bought 3 chunks of shares now, March, April and May. (Rest are held in Escrow)
So 16,500,000 shares at an average vwap of about 0.95p mean it cost them £156,750 so far.

Current sell price being 0.45p would mean they get £74,250 for the lot.

Placing them £82,500 in the red.

Wonder what they’re thinking?

That’s all good for those with a product to sell.

I'd rather someone building a position of size than a load of retail punters flip flopping in and out every percent.